TY - JOUR
T1 - Vaccination with altered peptide ligands of a Plasmodium berghei circumsporozoite protein CD8 T-cell epitope
T2 - A model to generate T cells resistant to immune interference by polymorphic epitopes
AU - Minigo, Gabriela
AU - Flanagan, Katie L.
AU - Slattery, Robyn M.
AU - Plebanski, Magdalena
PY - 2017/2/14
Y1 - 2017/2/14
N2 - Many pathogens, including the malaria parasite Plasmodium falciparum, display high levels of polymorphism within T-cell epitope regions of proteins associated with protective immunity. The T-cell epitope variants are often non-cross-reactive. Herein, we show in a murine model, which modifies a protective CD8 T-cell epitope from the circumsporozoite protein (CS) of Plasmodium berghei (SYIPSAEKI), that simultaneous or sequential co-stimulation with two of its putative similarly non-cross-reactive altered peptide ligand (APL) epitopes (SYIPSAEDI or SYIPSAEAI) has radically different effects on immunity. Hence, co-immunization or sequential stimulation in vivo of SYIPSAEKI with its APL antagonist SYIPSAEDI decreases immunity to both epitopes. By contrast, co-immunization with SYIPSAEAI has no apparent initial effect, but it renders the immune response to SYIPSAEKI resistant to being turned offby subsequent immunization with SYIPSAEDI. These results suggest a novel strategy for vaccines that target polymorphic epitopes potentially capable of mutual immune interference in the field, by initiating an immune response by co-immunization with the desired index epitope, together with a carefully selected "potentiator" APL peptide.
AB - Many pathogens, including the malaria parasite Plasmodium falciparum, display high levels of polymorphism within T-cell epitope regions of proteins associated with protective immunity. The T-cell epitope variants are often non-cross-reactive. Herein, we show in a murine model, which modifies a protective CD8 T-cell epitope from the circumsporozoite protein (CS) of Plasmodium berghei (SYIPSAEKI), that simultaneous or sequential co-stimulation with two of its putative similarly non-cross-reactive altered peptide ligand (APL) epitopes (SYIPSAEDI or SYIPSAEAI) has radically different effects on immunity. Hence, co-immunization or sequential stimulation in vivo of SYIPSAEKI with its APL antagonist SYIPSAEDI decreases immunity to both epitopes. By contrast, co-immunization with SYIPSAEAI has no apparent initial effect, but it renders the immune response to SYIPSAEKI resistant to being turned offby subsequent immunization with SYIPSAEDI. These results suggest a novel strategy for vaccines that target polymorphic epitopes potentially capable of mutual immune interference in the field, by initiating an immune response by co-immunization with the desired index epitope, together with a carefully selected "potentiator" APL peptide.
KW - Altered peptide ligand
KW - Antagonism
KW - Cross-reactivity
KW - Dendritic cell
KW - Malaria
KW - Plasmodium
KW - T cell
KW - Vaccine
UR - http://www.scopus.com/inward/record.url?scp=85014339624&partnerID=8YFLogxK
U2 - 10.3389/fimmu.2017.00115
DO - 10.3389/fimmu.2017.00115
M3 - Article
C2 - 28261200
AN - SCOPUS:85014339624
SN - 1664-3224
VL - 8
SP - 1
EP - 9
JO - Frontiers in Immunology
JF - Frontiers in Immunology
IS - FEB
M1 - 115
ER -